Fungal Lung Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major fungal lung diseases markets are expected to exhibit a CAGR of 3.07% during 2024-2034.
The fungal lung diseases market has been comprehensively analyzed in IMARC's new report titled "Fungal Lung Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Fungal lung diseases are conditions caused by the inhalation of fungal spores or the colonization of fungi within the respiratory system. These illnesses can affect various parts of the lungs, including the airways, pulmonary tissue, and the lining of the lung cavity. The diseases can range from mild infections to severe, life-threatening conditions, depending on the type of fungus involved. Some common symptoms associated with the ailments include persistent coughing, night sweats, chest pain, shortness of breath, fatigue, fever, weakness, unintentional weight loss, wheezing, etc. In rare cases, the fungi can spread to the central nervous system, leading to neurological indications such as headaches, confusion, seizures, or focal neural deficits. The diagnosis of fungal lung diseases typically involves a combination of clinical evaluation, medical history review, and laboratory analysis. Numerous imaging procedures, like chest X-rays and computed tomography (CT) scans, are also utilized to evaluate the lungs. These tests can help to identify abnormalities, such as infiltrates, nodules, or cavities, which may suggest a pulmonary infection. The healthcare provider may further recommend a lung tissue biopsy to confirm the diagnosis in patients.
The rising cases of chronic respiratory conditions, which can lead to structural changes in the lungs, thereby providing a favorable environment for the growth of microorganisms, are primarily driving the fungal lung diseases market. In addition to this, the increasing prevalence of weakened immune systems due to smoking, advancing age, prolonged or high-dose corticosteroid use, poorly controlled diabetes, etc., is creating a positive outlook for the market. Moreover, the widespread adoption of DNA sequencing techniques that help to detect the genetic makeup of fungal pathogens, including their virulence factors and drug resistance mechanisms, is further bolstering the market growth. Apart from this, the inflating application of immunotherapies, like interferon-gamma, to promote the activation and maturation of immune cells for recognizing and eliminating antigens in the lungs is acting as another significant growth-inducing factor. Additionally, the emerging popularity of liposomal amphotericin B therapy, since it allows for higher drug concentrations to be delivered to the site of infection, resulting in better treatment outcomes, is expected to drive the fungal lung diseases market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the fungal lung diseases market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for fungal lung diseases and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the fungal lung diseases market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the fungal lung diseases market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the fungal lung diseases market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current fungal lung diseases marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the fungal lung diseases market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the fungal lung diseases market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the fungal lung diseases market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of fungal lung diseases across the seven major markets?
What is the number of prevalent cases (2018-2034) of fungal lung diseases by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of fungal lung diseases by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with fungal lung diseases across the seven major markets?
What is the size of the fungal lung diseases patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of fungal lung diseases?
What will be the growth rate of patients across the seven major markets?
Fungal Lung Diseases: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for fungal lung diseases drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the fungal lung diseases market?
What are the key regulatory events related to the fungal lung diseases market?
What is the structure of clinical trial landscape by status related to the fungal lung diseases market?
What is the structure of clinical trial landscape by phase related to the fungal lung diseases market?
What is the structure of clinical trial landscape by route of administration related to the fungal lung diseases market?
The fungal lung diseases market has been comprehensively analyzed in IMARC's new report titled "Fungal Lung Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Fungal lung diseases are conditions caused by the inhalation of fungal spores or the colonization of fungi within the respiratory system. These illnesses can affect various parts of the lungs, including the airways, pulmonary tissue, and the lining of the lung cavity. The diseases can range from mild infections to severe, life-threatening conditions, depending on the type of fungus involved. Some common symptoms associated with the ailments include persistent coughing, night sweats, chest pain, shortness of breath, fatigue, fever, weakness, unintentional weight loss, wheezing, etc. In rare cases, the fungi can spread to the central nervous system, leading to neurological indications such as headaches, confusion, seizures, or focal neural deficits. The diagnosis of fungal lung diseases typically involves a combination of clinical evaluation, medical history review, and laboratory analysis. Numerous imaging procedures, like chest X-rays and computed tomography (CT) scans, are also utilized to evaluate the lungs. These tests can help to identify abnormalities, such as infiltrates, nodules, or cavities, which may suggest a pulmonary infection. The healthcare provider may further recommend a lung tissue biopsy to confirm the diagnosis in patients.
The rising cases of chronic respiratory conditions, which can lead to structural changes in the lungs, thereby providing a favorable environment for the growth of microorganisms, are primarily driving the fungal lung diseases market. In addition to this, the increasing prevalence of weakened immune systems due to smoking, advancing age, prolonged or high-dose corticosteroid use, poorly controlled diabetes, etc., is creating a positive outlook for the market. Moreover, the widespread adoption of DNA sequencing techniques that help to detect the genetic makeup of fungal pathogens, including their virulence factors and drug resistance mechanisms, is further bolstering the market growth. Apart from this, the inflating application of immunotherapies, like interferon-gamma, to promote the activation and maturation of immune cells for recognizing and eliminating antigens in the lungs is acting as another significant growth-inducing factor. Additionally, the emerging popularity of liposomal amphotericin B therapy, since it allows for higher drug concentrations to be delivered to the site of infection, resulting in better treatment outcomes, is expected to drive the fungal lung diseases market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the fungal lung diseases market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for fungal lung diseases and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the fungal lung diseases market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the fungal lung diseases market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the fungal lung diseases market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current fungal lung diseases marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the fungal lung diseases market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the fungal lung diseases market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the fungal lung diseases market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of fungal lung diseases across the seven major markets?
What is the number of prevalent cases (2018-2034) of fungal lung diseases by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of fungal lung diseases by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with fungal lung diseases across the seven major markets?
What is the size of the fungal lung diseases patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of fungal lung diseases?
What will be the growth rate of patients across the seven major markets?
Fungal Lung Diseases: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for fungal lung diseases drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the fungal lung diseases market?
What are the key regulatory events related to the fungal lung diseases market?
What is the structure of clinical trial landscape by status related to the fungal lung diseases market?
What is the structure of clinical trial landscape by phase related to the fungal lung diseases market?
What is the structure of clinical trial landscape by route of administration related to the fungal lung diseases market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 FUNGAL LUNG DISEASES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 FUNGAL LUNG DISEASES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 FUNGAL LUNG DISEASES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 FUNGAL LUNG DISEASES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 FUNGAL LUNG DISEASES - UNMET NEEDS
10 FUNGAL LUNG DISEASES - KEY ENDPOINTS OF TREATMENT
11 FUNGAL LUNG DISEASES - MARKETED PRODUCTS
11.1 List of Fungal Lung Diseases Marketed Drugs Across the Top 7 Markets
11.1.1 Cresemba (Isavuconazonium) - Basilea Pharmaceutica
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Vfend (Voriconazole) - Pfizer
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Sporanox (Itraconazole) - Janssen Pharmaceutical
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Cancidas (Caspofungin) - Merck & Co
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 FUNGAL LUNG DISEASES - PIPELINE DRUGS
12.1 List of Fungal Lung Diseases Pipeline Drugs Across the Top 7 Markets
12.1.1 Rezafungin acetate - Cidara Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Ibrexafungerp - Scynexis
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 PC945 - Pulmocide
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. FUNGAL LUNG DISEASES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. FUNGAL LUNG DISEASES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 FUNGAL LUNG DISEASES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Fungal Lung Diseases - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Fungal Lung Diseases - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Fungal Lung Diseases - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Fungal Lung Diseases - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Fungal Lung Diseases - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Fungal Lung Diseases - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Fungal Lung Diseases - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Fungal Lung Diseases - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Fungal Lung Diseases - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Fungal Lung Diseases - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Fungal Lung Diseases - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Fungal Lung Diseases - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Fungal Lung Diseases - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Fungal Lung Diseases - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Fungal Lung Diseases - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Fungal Lung Diseases - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Fungal Lung Diseases - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Fungal Lung Diseases - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Fungal Lung Diseases - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Fungal Lung Diseases - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Fungal Lung Diseases - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Fungal Lung Diseases - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Fungal Lung Diseases - Access and Reimbursement Overview
16 FUNGAL LUNG DISEASES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 FUNGAL LUNG DISEASES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 FUNGAL LUNG DISEASES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 FUNGAL LUNG DISEASES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 FUNGAL LUNG DISEASES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 FUNGAL LUNG DISEASES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 FUNGAL LUNG DISEASES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 FUNGAL LUNG DISEASES - UNMET NEEDS
10 FUNGAL LUNG DISEASES - KEY ENDPOINTS OF TREATMENT
11 FUNGAL LUNG DISEASES - MARKETED PRODUCTS
11.1 List of Fungal Lung Diseases Marketed Drugs Across the Top 7 Markets
11.1.1 Cresemba (Isavuconazonium) - Basilea Pharmaceutica
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Vfend (Voriconazole) - Pfizer
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Sporanox (Itraconazole) - Janssen Pharmaceutical
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Cancidas (Caspofungin) - Merck & Co
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 FUNGAL LUNG DISEASES - PIPELINE DRUGS
12.1 List of Fungal Lung Diseases Pipeline Drugs Across the Top 7 Markets
12.1.1 Rezafungin acetate - Cidara Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Ibrexafungerp - Scynexis
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 PC945 - Pulmocide
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. FUNGAL LUNG DISEASES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. FUNGAL LUNG DISEASES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 FUNGAL LUNG DISEASES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Fungal Lung Diseases - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Fungal Lung Diseases - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Fungal Lung Diseases - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Fungal Lung Diseases - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Fungal Lung Diseases - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Fungal Lung Diseases - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Fungal Lung Diseases - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Fungal Lung Diseases - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Fungal Lung Diseases - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Fungal Lung Diseases - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Fungal Lung Diseases - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Fungal Lung Diseases - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Fungal Lung Diseases - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Fungal Lung Diseases - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Fungal Lung Diseases - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Fungal Lung Diseases - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Fungal Lung Diseases - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Fungal Lung Diseases - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Fungal Lung Diseases - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Fungal Lung Diseases - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Fungal Lung Diseases - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Fungal Lung Diseases - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Fungal Lung Diseases - Access and Reimbursement Overview
16 FUNGAL LUNG DISEASES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 FUNGAL LUNG DISEASES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 FUNGAL LUNG DISEASES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
